At our institution, the cytomegalovirus (CMV) prophylaxis protocol for allogeneic bone marrow transplant (BMT) recipients who are CMV-seropositive or receive marrow from a CMV-seropositive donor consists of a surveillance bronchoscopy approximately 35 days posttransplant. Patients with a positive surveillance bronchoscopy for CMV receive pre-emptive ganciclovir. In order to determine the utility of other screening methods for CMV, we prospectively performed weekly CMV antigenemia, and blood, urine and throat cultures from time of engraftment to day 120 post-BMT in 126 consecutive patients. Pre-emptive ganciclovir was given to 11/81 patients (13.6%) because of a positive surveillance bronchoscopy for CMV. Results of CMV blood, urine and throat cultures and the antigenemia assay done prior to or at the time of the surveillance bronchoscopy were analyzed for their ability to predict the bronchoscopy result. The antigenemia test had the highest positive and negative predictive values (72% and 96%, respectively). The ability of these tests to predict CMV disease was evaluated in the 70 patients with a negative surveillance bronchoscopy who did not receive pre-emptive ganciclovir. Of 19 cases of active CMV disease, CMV antigenemia was positive in 15 patients (79%) a mean of 34 days preceding symptoms. Blood cultures were positive in 14/19 patients (74%) a mean of 31 days before onset of disease. CMV antigenemia is useful for predicting the surveillance bronchoscopy result, and also predicts the development of CMV disease in the majority of patients missed by the surveillance bronchoscopy. Keywords: CMV; antigenemia; surveillance Cytomegalovirus (CMV) is an important opportunistic pathogen in patients undergoing allogeneic bone marrow transplant (BMT). Treatment of established CMV disease is often unsuccessful. Even with aggressive combination therapy with ganciclovir and immunoglobulin, the mortality Correspondence: Dr T Mazzulli, Department of Microbiology, Mount Sinai Hospital, 600 University Ave, Toronto, Ontario, M5G 1X5, Canada Received 6 May 1998; accepted 24 July 1997 rate of CMV pneumonitis is reported to be 30-50%.
rate of CMV pneumonitis is reported to be 30-50%. 1, 2 This poor outcome has led to the use of numerous strategies aimed at preventing the development of active CMV disease. One approach has been to administer antiviral agents to all BMT recipients at risk of developing CMV disease. 3 Although demonstrated to be effective, this strategy results in the administration of antiviral therapy to a significant number of patients who would never have developed active CMV disease. A second approach has been to administer pre-emptive antiviral agents to patients in whom CMV is detected in surveillance specimens, such as blood and bronchoalveolar lavage (BAL) fluid prior to the development of symptoms. A strategy utilizing a day 35 post-BMT screening bronchoscopy in which pre-emptive ganciclovir is administered to all patients with a positive CMV culture of BAL fluid, has been shown to decrease the incidence of active CMV disease in allogeneic BMT. 4 However, this method is invasive, costly, may be associated with adverse effects related to bronchoscopy, and generally allows for only one or two determinations of CMV reactivation post-BMT. In addition, a significant proportion of patients with a negative screening bronchoscopy still develop active CMV disease. 4 Numerous other diagnostic tests for the early detection of CMV are currently available and include blood, urine and throat cultures, the CMV antigenemia assay, as well as molecular diagnostic assays such as PCR and hybridization assays. 5 , 6 The minimally invasive nature of such tests allows for multiple determinations over a period of time post-BMT to monitor for CMV reactivation. In order to establish the true predictive value of any of these tests, a cohort of BMT recipients ideally should be followed with sequential testing and receive no prophylactic or preemptive ganciclovir prior to the development of active CMV disease. However, in the presence of effective preemptive treatment strategies, 4 evaluation of newer assays in a surveillance and pre-emptive strategy is difficult to perform.
At our institution, all BMT patients who are CMV-seropositive or receive marrow from a CMV-seropositive donor undergo a surveillance bronchoscopy on day 35 post-BMT for the detection of CMV in BAL fluid. Any patient with a positive BAL fluid culture for CMV receives pre-emptive ganciclovir. 4 The clinical utility of other CMV tests for predicting the day 35 bronchoscopy result has not been previously assessed in a prospective manner. Therefore, the purpose of this study was to evaluate the correlation between weekly blood, urine and throat cultures for CMV, the CMV antigenemia assay and the result obtained by the surveillance bronchoscopy on day 35 post-BMT. The results of the weekly blood, urine and throat cultures for CMV and the CMV antigenemia assay were not disclosed to the treating clinician and were not used for clinical decision making. In addition, we evaluated the utility of these tests, performed in the 4 months post-BMT, for predicting the development of active CMV disease in those patients with negative surveillance bronchoscopy for CMV. Since this group did not receive antiviral therapy unless active CMV disease developed, the true predictive value of CMV antigenemia and blood, urine and throat cultures could be determined.
Methods

Patients
The study was reviewed and received ethics approval by the University of Toronto Human Subjects Review Committee. All patients gave written informed consent. One hundred and twenty-six consecutive patients receiving allogeneic BMT at a university-affiliated hospital were enrolled over an 18-month period. Mean patient age was 41.5 years (range 17-62 years) with 81 male and 45 female recipients. Underlying diagnosis necessitating transplant was AML (n = 29), CML (n = 39), ALL (n = 14), myelodysplastic syndrome (n = 14), non-Hodgkin's lymphoma (n = 12), multiple myeloma (n = 6), CLL (n = 5), aplastic anemia (n = 4), myelofibrosis (n = 2), and Fanconi's anemia (n = 1). Marrow transplantation was from an HLA-matched related donor in 109 patients and from an HLA-matched unrelated donor in 17 patients. All patients received cyclosporin A and methotrexate for graft-versus-host disease (GVHD) prophylaxis. 7 The 16 patients receiving marrow from unrelated donors also received prophylactic corticosteroids. 8 Patients who were CMV-seronegative received CMVnegative blood and blood products. All other patients received CMV unscreened blood and blood products.
Virology
Pre-transplant recipient and donor CMV serology was determined using the Abbott AxSYM enzyme immunoassay (Abbott Laboratories, Abbott Park, IL, USA). Shell vial and tube cultures for CMV and the CMV antigenemia assay were performed as previously described. 9 An antigenemia assay of у1 positive cell per slide (100 000 cells/slide) was considered a positive result. The number of positive cells per slide was counted up to a maximum of 500 positive cells. All testing was performed prospectively on fresh samples. Results of blood, urine and throat cultures and the CMV antigenemia assay were not disclosed to the treating physician.
Protocol
As part of the current CMV prevention protocol at our institution, all CMV-seropositive recipients and seronegative recipients of seropositive marrow undergo a day 35 surveillance bronchoscopy for CMV shell vial and tube culture of BAL fluid. Patients with a positive surveillance bronchoscopy are pre-emptively treated with a 2-week induction course of 5 mg/kg twice daily intravenous ganciclovir. If a follow-up bronchoscopy and BAL fluid culture are negative for CMV at the end of the 2 weeks of induction therapy, the patients receive an additional 8 weeks of maintenance therapy with ganciclovir 5 mg/kg/day. If the BAL fluid culture is still positive for CMV at the end of the 2 weeks of induction therapy, then the patients receive an additional 2 weeks of ganciclovir 5 mg/kg twice daily followed by 8 weeks of maintenance therapy. Intravenous immunoglobulin was not used for CMV prophylaxis. This protocol was followed throughout the study. All patients enrolled in this study, regardless of CMV serostatus, had shell vial and tube cultures of blood, urine and throat, and the CMV antigenemia assay performed weekly or at every clinic visit from day 21 to day 120 post-transplant. The decision to institute pre-emptive ganciclovir therapy was solely based on the results of the day 35 surveillance bronchoscopy. Treatment for CMV was initiated only for those patients who developed active disease as defined below.
Definitions of CMV
CMV infection was defined as recovery of CMV in any body fluid or tissue, or a positive CMV antigenemia. CMV disease was defined as evidence of CMV infection with associated signs and symptoms. Criteria for diagnosis of CMV disease were used as previously described. 10 CMV pneumonia was defined by the presence of clinical symptoms and compatible chest radiography together with CMV detected in BAL fluid or lung biopsy. Gastrointestinal disease was defined by symptoms referrable to the gastrointestinal tract together with CMV detection by culture or histopathology of biopsy specimens obtained from the gut. CMV viral syndrome was defined as unexplained fever with leukopenia or thrombocytopenia and a positive culture or antigenemia for CMV. 11 
Statistical analysis
The sensitivity, specificity, positive and negative predictive values of CMV isolation from blood, urine and throat, and for CMV antigenemia were determined for two separate outcomes using 2 ϫ 2 tables. First, the results of specimens collected on or prior to day 35 post-transplant were analyzed for their ability to predict the day 35 surveillance bronchoscopy result (this analysis excluded the patients who were donor and recipient seronegative for CMV (DϪ/RϪ) because they did not undergo a screening bronchoscopy). A second analysis looked at all patients who did not receive pre-emptive ganciclovir (patients with a negative day 35 surveillance bronchoscopy). In this group, results of CMV testing were analyzed for their ability to predict the development of active CMV disease within the first 6 months post-transplant. Specimen results obtained at or any time after development of CMV disease were excluded from this analysis. Receiver operating characteristic (ROC) curves were generated for the different tests by plotting the sensitivity of the test against 1-specificity. Sensitivity and specificity were calculated for various positive cut-off points for the antigenemia assay. An ideal diagnostic test would have a sensitivity and specificity of 1.0 and therefore would include the maximum area under an ROC curve. Areas under the ROC curve of each test were determined and compared with chance alone (sensitivity 0.5, specificity 0.5).
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Results
One hundred and twenty-six consecutive patients were evaluated. Pre-transplant donor (D) and recipient (R) CMV serostatus were as follows: Dϩ/Rϩ, 48 patients; DϪ/Rϩ, 22 patients; Dϩ/RϪ, 17 patients; and DϪ/RϪ, 39 patients. A total of 20 cases of active CMV disease occurred in the first 6 months post-transplant. Average time of onset was 81 days post-transplant (median 73 days; range 50-137 days). CMV disease was manifest as CMV pneumonitis (10 cases), CMV viral syndrome (five cases), gastrointestinal disease (three cases), and combined pneumonitis/gastrointestinal disease (two cases). Of 87 patients who were CMV-seropositive and/or received marrow from a CMVseropositive donor, a surveillance bronchoscopy for CMV was performed in 81, a mean of 36 days (range 33-43 days) post-transplant. Of the six patients who did not undergo a surveillance bronchoscopy, four patients died between day 23-33 post-transplant, and two patients missed their scheduled bronchoscopy for unknown reasons. Eleven of the 81 patients (13.6%) had a positive surveillance bronchoscopy for CMV and therefore received pre-emptive ganciclovir therapy. Two of these 11 patients developed CMV pneumonitis at 4 and 7.5 months post-transplant despite having received pre-emptive ganciclovir. In the first patient, ganciclovir therapy was interrupted after 3 weeks due to the development of neutropenia. The second patient completed a full 10-week course of pre-emptive ganciclovir. The remaining 115 patients (70 with a negative surveillance bronchoscopy for CMV, six who did not undergo a surveillance bronchoscopy, and 39 DϪ/RϪ patients) did not receive any form of ganciclovir prophylaxis. Active CMV disease developed in 19/70 (27%) of patients with a negative surveillance bronchoscopy. None of the DϪ/RϪ group developed CMV disease.
The ability of each of these tests to predict the surveillance bronchoscopy result is shown in Table 1 . Four Table 1 Ability of different CMV assays to predict the result of the surveillance screening bronchoscopy for CMV in allogeneic bone marrow transplant recipients
CMV test
Sensitivity % Specificity % PPV % NPV % Of 81 patients, 11 had a positive CMV culture of bronchoalveolar lavage (BAL) fluid and 70 had a negative result. Four patients with a negative culture of BAL fluid for CMV had no specimens collected for CMV or for the CMV antigenemia assay prior to the surveillance bronchoscopy. Surveillance bronchoscopy was performed a mean of 36 days (range 33-43 days) post-transplant. PPV = positive predictive value; NPV = negative predictive value.
patients who did not have any samples taken for CMV testing before their surveillance bronchoscopy could not be included in this analysis. Antigenemia was positive prior to or on the day of the positive surveillance bronchoscopy for CMV in 8/11 (73%) patients including the two patients who subsequently developed CMV disease. The antigenemia was positive a mean of 9 days (median 9 days; range 2-14 days) prior to the positive surveillance bronchoscopy. Blood culture was positive in 3/11 (27%), throat in 4/11 (36%) and urine in 1/10 (10%) of these patients. The antigenemia assay had the best positive and negative predictive value for the surveillance bronchoscopy (73% and 95%, respectively). Using a combination of all four tests for predicting the result of the surveillance bronchoscopy did not improve sensitivity over the antigenemia assay alone.
Of the patients with a negative surveillance bronchoscopy for CMV, three had a positive CMV antigenemia prior to their surveillance bronchoscopy (one of whom subsequently developed CMV pneumonitis, the other two remained asymptomatic). In addition, one patient had a positive blood culture for CMV and two patients had a positive urine culture for CMV prior to their negative surveillance bronchoscopy. None of these patients developed active CMV disease. One of four patients with a positive throat culture for CMV prior to their negative surveillance bronchoscopy developed active CMV disease.
A ROC curve for prediction of the surveillance bronchoscopy result is shown in Figure 1 . Using a higher positive cut-off value for antigenemia resulted in significantly decreased sensitivity. The 95% confidence interval (CI) for the area under the antigenemia ROC curve was 0.70-0.97. The 95% CI was 0.48-0.77 for blood culture, 0.46-0.66 for the urine culture, and 0.51-0.80 for the throat culture ROC curves. Only the antigenemia and the throat culture were significantly superior (P Ͻ 0.05) to chance alone for predicting the result of the surveillance bronchoscopy.
None of the 39 patients who were DϪ/RϪ for CMV developed CMV disease. One of these patients had a single positive antigenemia result (one positive cell/slide) and a second patient had a single positive urine culture. All other assays were negative for CMV in this group.
The sensitivity, specificity, positive and negative predictive values (PPV and NPV, respectively) for the different CMV tests for predicting disease in the 76 patients at risk for CMV but who did not receive ganciclovir prophylaxis are shown in Table 2 . In the 19 patients who developed CMV disease, the antigenemia assay was positive prior to the development of symptoms in 15 patients (79%). Antigenemia preceded development of CMV disease by a mean of 34 days (median 24 days; range 3-96 days). A positive blood culture preceded disease in 14/19 (74%) patients by a mean of 28 days (median 23 days; range 3-96 days). However, two of the patients who developed CMV disease that was not predicted by a positive antigenemia or blood culture (both tests negative) had no specimens collected in the 30 days prior to the development of CMV disease. If these two patients are excluded, the antigenemia test has a sensitivity of 88%, specificity 68%, PPV 45%, and NPV 95%. Throat cultures were positive in 9/19 (47%) patients a mean of 35 days prior (median 29 days; range 9-76) and urine in 11/15 (73%) patients a mean of 30 days prior to development of symptoms (median 27 days; range 2-76).
Since quantitative CMV antigenemia results were obtained, the sensitivity and specificity of various cut-off points for antigenemia were calculated. A ROC curve for CMV antigenemia and the other tests' ability to predict CMV disease in the 76 non-prophylaxed patients is shown in Figure 2 . Increasing the cut-off value for a positive antigenemia results in improved specificity but poorer sensitivity. For example, using a positive cut-off value for antigenemia of Ͼ2 positive cells/slide, the sensitivity was 63%, specificity 81%. PPV was 52% and NPV was 87%. Therefore, only 12/19 (63%) cases of CMV disease would have been predicted by the antigenemia assay. The 95% CI for 
Discussion
Our study demonstrates several key points: (1) the use of a day 35 surveillance bronchoscopy missed a significant number of cases of CMV disease; (2) CMV antigenemia was reasonably predictive of the day 35 BAL result; and (3) CMV antigenemia and blood cultures predicted the majority of the cases of CMV disease that were missed by the bronchoscopy. Of the 11 patients who had a positive surveillance bronchoscopy for CMV, eight were positive by antigenemia compared to four by throat culture, three by blood culture and only one by urine culture. Although three patients with a positive surveillance bronchoscopy for CMV were missed by the antigenemia assay, it is not known if these patients would have gone on to develop CMV disease or would have subsequently developed a positive antigenemia assay since they all received preemptive ganciclovir therapy. A previous study has demonstrated that at least 30% of patients with a positive surveillance bronchoscopy for CMV and who do not receive preemptive ganciclovir therapy do not develop CMV disease. 4 In our study, there were three positive antigenemia results associated with a negative surveillance bronchoscopy. However, one of these patients subsequently developed active CMV disease. Of the four tests (blood, urine and throat cultures, and CMV antigenemia), the antigenemia assay appeared to be the best test for predicting the surveillance bronchoscopy result. It was significantly (P Ͻ 0.05) better than chance alone.
The rate of CMV disease in the patients with a negative surveillance bronchoscopy (19/70; 27%) was only slightly higher than previously reported by Schmidt et al (21%). 4 However, our overall rate of positive surveillance bronchosopies (13.6%; 11/81) was substantially lower than reported in this previous study, in which 38.5% of patients had a positive surveillance bronchoscopy for CMV. This may be due in part to differences in induction and GVHD prophylaxis regimens. For example, in the study by Schmidt et al, 4 all patients received anti-lymphocyte immunotoxin for GVHD prophylaxis. Anti-lymphocyte products have been recognized as a risk factor for CMV reactivation and CMV disease in solid organ transplant recipients. 13 At our institution no patient received an anti-lymphocyte product for GVHD prophylaxis. The fact that our rate of CMV disease in patients who had a negative surveillance bronchoscopy was similar to that previously reported suggests that the low rate of positive surveillance bronchoscopy for CMV in our cohort of patients was not due to the inability of the laboratory assays to detect CMV in the BAL fluid obtained during the surveillance bronchoscopy. Table 2 Ability of different CMV assays to predict the development of CMV disease in 76 allogeneic bone marrow transplant recipients not receiving pre-emptive ganciclovir
CMV test
Sensitivity % Specificity % PPV % NPV %
The surveillance bronchoscopy result is only a surrogate marker of CMV reactivation, and the true utility of a test is in its ability to predict the development of active CMV disease. Since only 11 patients in our study received preemptive ganciclovir therapy, this left a cohort of non-prophylaxed patients in whom the utility of the culture tests and the antigenemia assay could be determined. There were 19 cases of CMV disease in this group of patients, emphasizing the need for additional or alternative diagnostic tests to the surveillance bronchoscopy. In the 19 patients with CMV disease, the antigenemia assay would have predicted disease in 15 patients, a mean of 34 days prior to the development of symptoms (range 3-96 days). Blood culture would have predicted disease in 14 of these patients a mean of 31 days prior to the development of symptoms (range 3-96 days). If the two patients who had no specimens sent for testing in the month prior to the development of disease are excluded, the antigenemia predicted disease in 15/17 (88%) patients and blood culture in 14/17 (82%) patients. However, even with frequent sampling, two of our patients remained antigenemia-negative and three patients remained blood culture negative until the development of symptoms. This suggests that a small proportion of patients remain culture and/or antigenemia negative preceding the development of active CMV disease. A possible explanation for this may be that some cases of CMV pneumonitis or gastrointestinal disease represent local reactivation and may not be accompanied by detectable viremia. 14, 15 An approach which utilizes multiple different tests in combination to guide pre-emptive therapy may enhance sensitivity, but might also result in decreased specificity. For example, a pre-emptive strategy based on the combination of blood, urine and throat cultures and the CMV antigenemia test would have predicted CMV disease in 18/19 patients. However, an additional 36 patients would also have a positive result with at least one of these tests without the subsequent development of active CMV disease. Therefore, if pre-emptive treatment was based on the results of this combination of tests, the majority of patients would receive ganciclovir unnecessarily.
Positive predictive values for the development of CMV disease ranged from 33% to 54% with the blood culture and the antigenemia assay having the highest positive predictive values. Since the cohort of non-prophylaxed patients excluded a high risk group (those with a positive day screening bronchoscopy), the positive predictive value may be an underestimation of the true value if the entire cohort had not received any form of pre-emptive therapy. Nonetheless, at least 50% of patients with a positive antigenemia assay or a positive throat, urine or blood culture may not go on to develop CMV disease. These results are similar to previously reported positive predictive values reported for blood urine and throat cultures in BMT patients. 14 The predictive value of the antigenemia assay has not been adequately assessed in a large cohort of BMT patients who are not receiving pre-emptive ganciclovir. Boeck et al 16 reported a positive predictive value of CMV antigenemia of 68% for the development of either active CMV disease or CMV viremia. Patients in this study received preemptive ganciclovir based on the results of CMV blood culture. In our study, the results of antigenemia, and cultures of blood, urine and throat were not disclosed to the treating physician and in no case was pre-emptive therapy based on the results of these tests. This allows for a closer approximation of the value of these tests for predicting CMV disease. In this cohort of patients, if the CMV antigenemia were used for the basis of pre-emptive therapy, 15 of the 19 patients who developed CMV disease would have received pre-emptive ganciclovir. An additional 18 patients would have received ganciclovir unnecessarily since they did not go on to develop CMV disease. Also, 8/11 patients with a positive surveillance bronchoscopy would have received pre-emptive ganciclovir. Therefore, a pre-emptive strategy based on the antigenemia assay would have the probable advantage of preventing the majority of cases of CMV disease but would also result in the administration of pre-emptive antiviral therapy to a number of patients who would not have developed symptomatic CMV disease.
The antigenemia assay provides quantitative information that may be potentially useful. In solid organ transplantation, a correlation between very high levels of CMV antigenemia and the development of CMV disease has been reported. 5, 17 However, three of the 19 patients who developed CMV disease had only one or two positive cells/slide preceding disease development. Therefore, low grade antigenemia may be the only warning for the development of subsequent disease, and these results should not be dismissed when employing a pre-emptive strategy based on CMV antigenemia. In our study, of patients who had a positive antigenemia result, those who subsequently developed active CMV disease had significantly higher antigenemia levels than those who remained asymptomatic.
In conclusion, in this cohort of BMT patients, a preemptive strategy based on the result of a surveillance bronchoscopy for CMV missed a significant number of patients who subsequently developed CMV disease in the first 6 months post-transplant. The majority of these patients would have received pre-emptive ganciclovir if CMV antigenemia or CMV blood culture were utilized as a screening tool. Of the four screening methods evaluated (blood, urine, throat cultures and antigenemia), the antigenemia test best correlated with the surveillance bronchoscopy result. In addition, the antigenemia predicted the majority of cases of active CMV disease which were missed by the surveillance bronchoscopy. However, the optimum laboratory test(s) on which to base a pre-emptive screening strategy is not known. It is also not known what is the optimum intervention (ie drug, dose and duration) that should be instituted in a pre-emptive strategy. Different pre-emptive strategies should be compared in a prospective fashion to determine their efficacy and to allow for an economic analysis.
